重组人尿激酶治疗急性ST段抬高型心肌梗死的疗效及对血清C反应蛋白、补体C3的影响  

Analysis of the impact of C reactive protein and serum complement C3 ST segment elevation in acute myocardial infarction patients treated with recombinant human urokinase

作　　者：冷闰杰[1] 刘晓红[1] 李岩[1] 鲁俊红[1] 边小春[1] 

机构地区：[1]新疆克拉玛依市中心医院心血管内科,834000

出　　处：《疑难病杂志》2016年第2期135-138,共4页Chinese Journal of Difficult and Complicated Cases

摘　　要：目的观察重组人尿激酶治疗急性ST段抬高型心肌梗死(STEMI)的疗效及对血清C反应蛋白、补体C3的影响。方法 2013年6月—2015年6月新疆克拉玛依市中心医院心血管内科收治STEMI患者90例,采用系统随机化法分为对照组45例和观察组45例。对照组采用常规治疗,观察组在常规治疗基础上采用重组人尿激酶进行治疗。对2组患者治疗后不同时间段血管再通情况、治疗前后血脂水平、ET-1、NO、hs-CRP及C3水平进行对比分析,并比较心血管事件、不良反应发生情况。结果治疗后印min、90 min及120 min,观察组血管再通率均明显高于对照组(P<0.05)。与治疗前相比,2组患者的TG、TC、LDL-C、ET-1及NO均有显著改善,且观察组改善情况明显优于对照组,差异均有统计学意义(P<0.05,P<0.01)。与治疗前相比,2组患者的hs-CRP及C3水平均有显著改善(P<0.05),且观察组患者的改善情况明显优于对照组(P<0.05)。观察组再发心肌梗死、心绞痛、严重心律失常的发生率明显低于对照组(P<0.05),而心力衰竭发生率及病死率与对照组相比无明显差异(P>0.05)。观察组肝功能异常、肌痛的发生率为0、8.88%,明显低于对照组的11.11%、22.22%(P<0.05);2组患者乏力、消化道反应的发生率相比差异无统计学意义(P>0.05)。结论重组人尿激酶治疗STEMI患者可以提高冠状动脉的开通率及优化患者的脂质水平,且不良反应小,临床推广和使用价值大。Objective To observe the effect of recombinant human urokinase on acute ST segment elevation myocardial infarction（STEM） and its effect on the serum C reactive protein and complement C3.Methods From June 2013 to June2015,90 patients with STEMI were randomly divided into the control group and the observation group with 45 cases of patients in each group in the Central Hospital of Karamav Xinjiang Autonomous Region,The control group was treated with routine treatment,and the observation group was treated with recombinant human urokinase on the basis of conventional treatment.After treatment,the patients＇ vascular recanalization at different time,before and after treatment lipid levels,and ET-1,NO and hs CRP and C3 levels and cardiovascular events occurred,adverse reactions were compared and analyzed in the two groups.Results After the treatment of 60 min,90 min and 120 min in the observation group,the recanalization rate was significantly higher than that of the control group（P〈0.05）.Compared with before treatment,2 groups of patients＇ TC,TG,LDL-C,ET-1 and NO were significantly improved,and the observation group improved significantly better than the control group（P〈0.05,P〈 0.01）.Two groups of patients＇ hs CRP and C3 levels were significantly improved compared to before treatment（P〈0.05）,and observation group improved significantly heller than the control group（P〈0.05）.The observation group＇s incidence of myocardial infarction,angina pectoris,arrhythmia were significantly lower than those of the control group（P〈0.05）.and the occurrence of heart failure rate and mortality rate showed no significant difference with the control group（P〉0.05）.Observation group＇s liver function abnormalities,myalgia＇s incidence rate was 0,8.88%,which was significantly lower than that in the control group of 11.11%and 22.22%（P〈0.05）;2 group patients＇ fatigue,digestive tract reaction incidence showed no statistically significant difference（P〉0.05）.Conclusion Recombinant h

关 键 词：重组人尿激酶 急性ST段抬高型心肌梗死 溶栓治疗 

分 类 号：R542.22[医药卫生—心血管疾病]